Recursion Pharmaceuticals, Inc. RXRX
3.74
(0.15)
(3.86%)
as of 25 Sep
- Market cap
- $2.1B
- P/E
- 0.0×
Follow RXRX
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
49.93 | 24.51 | 24.47 | 35.62 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(18.59) | (39.72) | (20.04) | (18.44) | |
P/B ratio |
2.08 | 1.62 | 1.59 | 2.14 | |
Price to Tangible BV |
3.88 | 2.78 | 2.85 | 4.14 | |
EV/Sales |
35.03 | 14.62 | 14.64 | 25.66 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.47) | (2.94) | (3.03) | (4.02) | |
EV/FCF |
(3.40) | (2.87) | (2.96) | (3.97) | |
Quick Ratio |
4.42 | 5.23 | 5.19 | 4.72 | |
Current Ratio |
4.60 | 5.50 | 5.47 | 5.03 | |
Net Debt/EBITDA |
4.31 | 8.31 | 6.00 | 4.68 | |
Debt/Assets |
0.85% | 0.65% | 0.54% | 0.39% | |
Debt/Equity |
0.01 | 0.01 | 0.01 | 0.01 | |
Asset Turnover |
0.04 | 0.05 | 0.05 | 0.04 | |
Operating CF/Net income |
0.72 | 0.43 | 0.69 | 0.81 | |
Capex/Depreciation |
(0.01) | (0.06) | (0.02) | (0.11) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
2,339.36% | 269.96% | 1,358.10% | 1,168.37% | |
Selling, General and Administrative Expense of Revenue |
804.41% | 94.71% | 534.47% | 541.50% | |
Intangible Assets out of Total Assets |
0.35 | 0.32 | 0.34 | 0.37 | |
Share Based Compensation of Revenue |
487.79% | 66.87% | 343.25% | 254.21% | |
Graham Net Nets |
0.17 | 0.26 | 0.24 | 0.16 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(36.89%) | (36.19%) | (39.09%) | (28.34%) | |
Free Cash Flow Yield |
(20.64%) | (20.79%) | (20.19%) | (18.13%) | |
Revenue per Share |
0.01 | 0.08 | 0.01 | 0.01 | |
Operating CF per Share |
(0.26) | (0.10) | (0.15) | (0.20) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.26) | (0.11) | (0.15) | (0.20) | |
Cash per Share |
1.48 | 1.67 | 1.25 | 1.03 | |
Shareholders Equity per Share |
2.34 | 2.53 | 1.94 | 1.72 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.34 | 2.53 | 1.94 | 1.72 | |
Free Cash Flow |
(117.60) | (47.32) | (81.44) | (107.91) | |
Working Capital |
559.00 | 665.14 | 579.86 | 483.58 | |
Capital Expenditures |
(0.24) | (1.24) | (0.34) | (1.96) | |
Net Current Asset Value |
361.53 | 469.58 | 394.80 | 305.80 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.05 | 0.04 | 0.05 | 0.26 | |
Net Profit Margin |
(3,135.32%) | (304.24%) | (1,815.57%) | (1,708.02%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
12.08 | 36.91 | 29.85 | 18.00 | |
Average Payables |
8.10 | 19.87 | 22.72 | 15.99 | |
Average Assets |
1,063.01 | 1,461.36 | 1,322.38 | 1,257.51 | |
Average Common Equity |
785.75 | 1,082.82 | 979.36 | 917.07 |
Columns are period end dates